Nasi eksperci
Flavio Guzmán, M.D.
Editor & CEO
Psychopharmacology Institute
Biografia
Nie znaleziono biografii.
Publikacje Flavio Guzmán, M.D.
Q1 2026 w przeglądzie: milsaperydon, agoniści receptora GLP-1 i zuranolonu
0,50 punktów CME
Why did the FDA approve milsaperidone if it offers no clinical advantage over iloperidone? What does the FDA's removal of the GLP-1 suicidality warning mean for your practice? How does ACOG's updated guidance position zuranolone for severe postpartum depression?
Flavio Guzmán, M.D.
Psychopharmacology Institute
Zobacz więcej informacji
Przewodnik po wenlafaksynie: farmakologia, wskazania, zasady dawkowania i działania niepożądane
0,50 punktów CME
This guide covers pharmacodynamics, pharmacokinetics, dosage forms, indications, side effects, and use in special populations. It also discusses venlafaxine's mechanism of action, metabolism, and FDA-approved and off-label uses.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Zobacz więcej informacji
Cytalopram i escytalopram: podsumowanie kluczowych różnic i podobieństw
0,50 punktów CME
This article provides an in-depth comparison of citalopram and escitalopram, covering their chemical composition, pharmacokinetics, FDA-approved indications, off-label uses, potential side effects, and the risk of QT prolongation associated with both drugs. Furthermore, it addresses crucial considerations for prescribing these medications to specific patient populations.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Zobacz więcej informacji
Praktyczny przewodnik po fluoksetynie: farmakologia, wskazania, zasady dawkowania i działania niepożądane
0,50 punktów CME
Fluoxetine is a potent serotonin reuptake inhibitor with a long half-life. It is FDA-approved for depression, OCD, panic disorder and bulimia. Fluoxetine also has off-label uses like treating repetitive behaviors in autism. This guide covers fluoxetine's pharmacology, dosing, side effects and use in special populations.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Zobacz więcej informacji
Praktyczny przewodnik po fluwoksaminie: farmakologia, wskazania, zasady dawkowania i działania niepożądane
0,50 punktów CME
Fluvoxamine (Luvox) is approved for OCD in both pediatric and adult patients in the U.S. There is no definitive evidence suggesting it is more effective than other SSRIs for OCD. It is also approved for depression in the UK. Fluvoxamine is an inhibitor of CYP1A2 and should not be combined with MAOIs.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Zobacz więcej informacji
